Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysisResearch in context

Summary: Background: With increasing recognition of the value of incorporating prognostic markers into amyotrophic lateral sclerosis (ALS) trial design and analysis plans, there is a pressing need to understand which among the prevailing clinical and biochemical markers have real value, and how the...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Michael Benatar, Eric A. Macklin, Andrea Malaspina, Mary-Louise Rogers, Eran Hornstein, Vittoria Lombardi, Danielle Renfrey, Stephanie Shepheard, Iddo Magen, Yahel Cohen, Volkan Granit, Jeffrey M. Statland, Jeannine M. Heckmann, Rosa Rademakers, Caroline A. McHutchison, Leonard Petrucelli, Corey T. McMillan, Joanne Wuu, Lauren Elman, John Ravits, Jonathan Katz, Jaya Trivedi, Andrea Swenson, Ted M. Burns, James Caress, Carlayne Jackson, Samuel Maiser, Erik P. Pioro, Yuen So
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-10-01
Edice:	EBioMedicine
Témata:	Prognostic biomarkers Context-of-use ALS clinical trials Neurofilament
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2352396424003591
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!